Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14318-14328

  Trerotola, Marco ^a,b,e   Ganguly, Kirat K ^a,b   Fazli, Ladan ^c   Fedele, Carmine ^a,b   Lu, Huimin ^a,b   Dutta, Anindita ^a,b   Liu, Qin ^a,d   De Angelis, Tiziana ^a,b   Riddell, Luke W ^a,b   Riobo, Natalia A ^b   Gleave, Martin E ^c   Zoubeidi, Amina ^c   Pestell, Richard G ^b   Altieri, Dario C ^a,d   Languino, Lucia R ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d WISTAR INSTITUTE   (United States)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Exosome; Gleason grade; Metastasis; PT2 pT3 pT4 prostate cancer; TRAMP

Indexed keywords

ALPHA5 INTEGRIN; BETA1 INTEGRIN; BETA5 INTEGRIN; CD51 ANTIGEN; FIBRONECTIN; FOCAL ADHESION KINASE; MEMBRANE PROTEIN; TRANSMEMBRANE GLYCOPROTEIN TROP 2; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TROP2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CANCER STAGING; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MALE; MICE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 84931037624     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3960     Document Type: Article

References (38)

1. Edge SB and American Joint Committee on Cancer. (2010). AJCC cancer staging manual. (New York: Springer).
2. Sobin LH, Gospodarowicz MK, Wittekind C and Cancer IUa. (2010). TNM classification of malignant tumours. (Chichester, West Sussex, UK; Hoboken, NJ: Wiley- Blackwell).
3. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E and Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013; 3:849-861.
4. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL and Nagle RB. Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol. 1994; 145:167-174.
5. Murant SJ, Handley J, Stower M, Reid N, Cussenot O and Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer. 1997; 33:263-271.
6. Goel HL, Underwood JM, Nickerson JA, Hsieh CC and Languino LR. β1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. J Cell Physiol. 2010; 224:210-217.
7. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD and Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Res. 2008; 68:2329-2339.
8. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H and Miyake M. Significance of integrin α5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res. 2000; 6:96-101.
9. Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW and Thijssen VL. Integrin expression profiling identifies integrin α5 and β1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer. 2010; 9:152.
10. Kuwada SK and Li X. Integrin α5/β1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol Biol Cell. 2000; 11:2485-2496.
11. Morozevich G, Kozlova N, Cheglakov I, Ushakova N and Berman A. Integrin α5β1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP- 2 collagenase activity. Cell Cycle. 2009; 8:2219-2225.
12. Akiyama SK. Integrins in cell adhesion and signaling. Hum Cell. 1996; 9:181-186.
13. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M and Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151:1542-1556.
14. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18:883-891.
15. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654-659.
16. Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A and Languino LR. Trop-2 promotes cancer metastasis by modulating β1 integrin functions. Cancer Res. 2013; 73:3155-3167.
17. Trerotola M, Li J, Alberti S and Languino LR. Trop- 2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 2012; 227:3670-3677.
18. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G and Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008; 99:1290-1295.
19. Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S, Mironenko O, Kacinski BM, Perkins AS and Sapi E. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest. 2004; 84:320-331.
20. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K and Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006; 12:3057-3063.
21. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, La Sorda R, Lattanzio R, de Lange R, Weidle U, Piantelli M and Alberti S. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2012; 32:222-233.
22. Ellis L, Lehet K, Ku S, Azabdaftari G and Pili R. Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience. 2014; 1:609-613.
23. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA. 1995; 92:3439-3443.
24. Fedele C, Singh A, Zerlanko BJ, Iozzo RV and Languino LR. The αvβ6 Integrin Is Transferred Intercellularly via Exosomes. J Biol Chem. 2015; 290:4545-4551.
25. Bijnsdorp IV, Geldof AA, Lavaei M, Piersma SR, van Moorselaar RJ and Jimenez CR. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles. 2013; 2.
26. Clayton A, Turkes A, Dewitt S, Steadman R, Mason MD and Hallett MB. Adhesion and signaling by B cell-derived exosomes: the role of integrins. FASEB J. 2004; 18:977-979.
27. Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH, Chen HW, Wu CC, Chung T, Hsu CW, Chen CD, Chang YS, Chang PL and Chen YT. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 2012; 11:5611-5629.
28. Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H and Simpson RJ. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics. 2013; 12:587-598.
29. Cox BD, Natarajan M, Stettner MR and Gladson CL. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem. 2006; 99:35-52.
30. Lipinski M, Parks DR, Rouse RV and Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981; 78:5147-5150.
31. Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M and Alberti S. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 2008; 68:8113-8121.
32. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA and Ghosh PM. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007; 13:3860-3867.
33. Goel H, Sayeed A, Breen M, Zarif MJ, Garlick DS, Leav I, Davis RJ, Fitzgerald TJ, Morrione A, Liu Q, Dicker A, Altieri DC and Languino LR. β1 integrins mediate resistance to ionizing radiation by inhibiting JNK. J Cell Physiol. 2013; 228:1601-1609.
34. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M and Greenberg NM. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res. 2008; 68:3495-3504.
35. Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A and Languino LR. β1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res. 2005; 65:6692-6700.
36. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
37. Aota S, Nomizu M and Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem. 1994; 269:24756-24761.
38. Thery C, Amigorena S, Raposo G and Clayton A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids (John Wiley & Sons, Inc).